Onkološki inštitut Ljubljana (OILJ)
PDF
  • Current opinion on pixantrone in the treatment of non-Hodgkin B-cell lymphoma [Elektronski vir]
    Jezeršek Novaković, Barbara ; Boltežar, Lučka ; Novaković, Aleksander, zdravnik
    : Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true ... for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and realworld studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas
    Vir: Therapeutics and clinical risk management [Elektronski vir]. - ISSN 1178-203X (Vol. 17, 2021, str. 183-192)
    Vrsta gradiva - e-članek
    Leto - 2021
    Jezik - angleški
    COBISS.SI-ID - 54015235

    Povezava(-e):

    https://www.dovepress.com/articles.php?article_id=62694
    DOI

Vnos na polico